RxDoctor Payments Data

Renato Apolito, MD

Cardiovascular Disease · Neptune, NJNPI 1457570731

Payments from drug & device makers

$37,221in general payments, 2019–2025

Across 1,138 payments — averaging $32.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • AstraZeneca$8K
  • Abbott$4K
  • Abiomed$2K
  • Novartis$2K
  • Johnson & Johnson$1K
  • plus $9K from 42 others

What the payments were for

  • Speaking & faculty fees$7,20025%
  • Food & beverage$21,57175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,221 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$945,004
Medicare patients
2,092
Services billed
8,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban509$632,592
VyndamaxTafamidis17$510,465
XareltoRivaroxaban259$323,067
Repatha SureclickEvolocumab122$122,077
BrilintaTicagrelor95$94,935
EntrestoSacubitril/Valsartan72$84,306
FarxigaDapagliflozin Propanediol70$72,024
MultaqDronedarone Hcl34$57,447
Praluent PenAlirocumab38$42,136
VascepaIcosapent Ethyl40$24,480
Rosuvastatin Calcium807$14,866
Metoprolol Succinate864$14,016
Atorvastatin Calcium908$11,334
Valsartan304$10,630
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide133$7,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$747$1,143,057526 claims
Johnson & JohnsonXarelto$1,293$323,067259 claims
AstraZenecaBrilinta, Farxiga, Crestor$7,647$173,002189 claims
NovartisEntresto$1,800$84,30672 claims
Sanofi-aventis U.S. LLCMultaq$257$57,44734 claims
Boehringer IngelheimPradaxa$401$4,17320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →